Wound Care News

By Industry News

Toronto, CANADA – July 9, 2020 – MolecuLight Inc., creator of a device for point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces the launch of its new i:X Sterile Surgical Sleeve Convenience Kit for imaging bacteria in wounds using the MolecuLight i:X in a surgical and/or isolation setting. The convenience kit includes a unique disposable surgical sleeve that is fitted to neatly shroud the i:X device via an adapter to align the optics of the i:X to the sleeve. It is made of novel, optically-clear material so it doesn't interfere or degrade the fluorescence signal or image quality of the device. The surgical sleeve is now available to all customer sites in the US and Canada that want to perform bacterial imaging in these clinical settings and enables wound care practitioners to safely use the MolecuLight i:X to image wounds (both standard and fluorescence imaging) in a sterile field by providing a sterile barrier between the i:X device and the patient.

By Industry News

Miami, FL – June 30, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the initiation of the first of two planned multi center randomized controlled Phase 3 Clinical Trials that will be conducted at 20 investigational sites across the U.S. with an enrollment of 220 patients in each trial. These trials, titled AMBULATE DFU and AMBULATE DFU II, will study the benefits and risks of using TTAX01 to achieve complete wound closure of complex non-healing DFUs with high-risk factors of ulcer depth indicating exposed bone, tendon, muscle, and/or joint capsule, and clinical suspicion of osteomyelitis.

By Marcia Nusgart, RPh; Lee C. Rogers, DPM; Mark D. Iafrati, MD, FACS; Paul J. Kim, DPM, MS, FACFAS; Karen Ravitz, JD; Stephanie Woelfel, PT, DPT, CWS, FACCWS; and Emily Greenstein, APRN,CNP, CWON

On May 7, 2020, the Alliance of Wound Care Stakeholders presented a round table discussion with frontline experts to discuss the challenges and opportunities clinicians are facing during the COVID-19 pandemic. The discussion reviewed the significant changes wound care professionals are undergoing, a review of relevant regulatory flexibilities, and the Alliance's role in ensuring that wound care is identified as "essential" care, rather than "elective." A question and answer session followed the panels' discussion; the following represents some of the most frequently asked questions.

By Industry News

Edison, N.J. – June 25, 2020 – MTF Biologics, a global nonprofit organization providing tissue and organ donation, transplantation, and research, today announced that new positive coverage decisions by Aetna, Centene Corporation, WellCare and Tufts Health Plan will provide greater access to its human placental and dermal allografts, AmnioBand® and AlloPatch®, for the treatment of diabetic foot ulcers (DFUs).

By Industry News

Toronto, Canada– June 15, 2020 – MolecuLight Inc., a provider of point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces the availability of its MolecuLight i:X® platform to 9,000 healthcare facilities in the US through its new commercial arrangement with MAGNET GROUP GPO.

By Industry News

Toronto, CANADA – June 11, 2020 – MolecuLight Inc., the creator of a point-of-care fluorescence imaging device for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X imaging procedure for point-of-care real-time fluorescence wound imaging for bacterial presence, location and load (CPT® code 0598T (Category III)). The new APC code is effective July 1, 2020 and enables facility reimbursement under the Medicare Hospital Outpatient Prospective Payment System (OPPS), with a 2020 hospital outpatient payment rate of approximately $253.10 USD. This is in addition to the two category III CPT codes (0598T and 0599T), which also become active on July 1, 2020, that enable physicians to request payment from payers for their work providing the MolecuLight i:X imaging procedure.

By Industry News

The Wound Healing Fondation shares news on the Thomas K Hunt lecture, their COVID-19 patient tips, and new Board of Directors members.

By Industry News

June 2, 2020 – Smith+Nephew, the global medical technology business, announced the publication of a health economic study in Wound Management and Prevention, which states that the use of PICO◊ Single Use Negative Pressure Wound Therapy System (sNPWT) is estimated to be highly cost effective when compared with traditional NPWT (tNPWT), and may therefore provide opportunity to reduce the economic burden of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).

By Industry News

Miami, FL – June 1, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company, announced today the results from the one-year follow-up study to their Phase 2 open label, multicenter pilot study of Cryopreserved Umbilical Cord allograft TTAX01. The objectives of the study were to examine the safety and efficacy of TTAX01, plus standard of care, in achieving complete wound closure of complex non-healing Diabetic Foot Ulcers (DFUs) with evidence of exposed bone, tendon, muscle and/or joint capsule and clinical suspicion of osteomyelitis. Results of this one-year study are published in the peer-reviewed journal Wound Repair and Regeneration.

By Industry News

Miami, FL – February 24, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today the results from a single-center, retrospective case-controlled series authored by Christopher M. Stewart, MD. The study, titled “The Use of Cryopreserved Umbilical Cord in Open Reduction and Internal Fixation of Calcaneus Fractures,” was published in the SunKrist Journal of Trauma, Emergency Medicine and Acute Care. Analysis found that the overall complication rate in a controlled group of 20 consecutive patients was 35 percent, compared to a complication rate of 10 percent in the cUC group of patients when CLARIX was used as an adjunct to help decrease wound complications, re-operations, and infection rates.